Drug Approval | November 01, 2021
Sun Pharma's Winlevi available in the US
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The NFI is published to promote the rational use of medicines in the country.
The combined entity will have 12 hospitals with 3,666 beds
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Subscribe To Our Newsletter & Stay Updated
